Clinical Trials in Boston

Showing 2501-2520 of 17,836 trials

A Novel Vaccine (EO2463) as Monotherapy and in Combination, for Treatment of Patients With Indolent Non-Hodgkin Lymphoma

NCT04669171

The purpose of this study is to define the recommended Phase 2 Dose, safety, tolerability, immunogenicity, and preliminary efficacy of EO2463 during monotherapy and in combination with lenalidomide and/or rituximab in patients with indolent NHL

Follicular LymphomaMarginal Zone Lymphoma

Enterome80 participantsStarted Jul 2021

Boston, Massachusetts, United States • Rochester, Minnesota, United States • Rochester, New York, United States +9 more locations

Active Not RecruitingPhase 1< 1 mile

Tuvusertib (M1774) in Participants With Metastatic or Locally Advanced Unresectable Solid Tumors (DDRiver Solid Tumors 301)

NCT04170153

This is an open-label, Phase I, first-in-human (FIH) multicenter, clinical study conducted in multiple parts to establish the safety, tolerability and pharmacokinetic/pharmacodynamic (PK/PD) profile (with and without food) and early signs of efficacy of Tuvuseritib (M1774) as monotherapy and in combination with the poly (ADP-ribose) polymerase (PARP) inhibitor niraparib.

Metastatic or Locally Advanced Unresectable Solid Tumors

EMD Serono Research & Development Institute, Inc.161 participantsStarted Dec 2019

Boston, Massachusetts, United States • Austin, Texas, United States • Dallas, Texas, United States +13 more locations

A Novel Vaccine (EO2463) as Monotherapy and in Combination, for Treatment of Patients With Indolent Non-Hodgkin Lymphoma

Tuvusertib (M1774) in Participants With Metastatic or Locally Advanced Unresectable Solid Tumors (DDRiver Solid Tumors 301)

Find Trials by Condition in Boston

A Study of PHN-010 in Patients With Advanced Solid Tumors

Infliximab for Treatment of Immune Checkpoint Inhibitor Colitis

OsteoPorotic fracTure preventION System (OPTIONS) Research Study

Evaluation of Revumenib in Participants With Colorectal Cancer and Other Solid Tumors

A Study to Evaluate the Efficacy and Safety of ABC008 for Inclusion Body Myositis

BCL2i CLAG-M in R/R Acute Myeloid Leukemia

Memory-like Natural Killer (NK) Cell Therapy in Patients With Renal Cell Carcinoma or Urothelial Carcinoma

Venetoclax Plus Inotuzumab for B-ALL

A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study

A Study Of Changes In PD-L1 Expression During Preoperative Treatment With Nab-Paclitaxel And Pembrolizumab In Hormone Receptor-Positive Breast Cancer

Feasibility Testing of a Tai Chi Program for Chemotherapy-Induced Peripheral Neuropathy Treatment (TCT)

Adjunctive Mindfulness During Opioid Tapering for patientS With Chronic Pain (The AMOS Study)

A Study of Modakafusp Alfa (TAK-573) Given by Itself and Together With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors

A Study of a Novel Iron-based Phosphate Binder AP301 in Patients With Hyperphosphatemia in the U.S. and China

A Study of Eptinezumab in Participants With Migraine and Medication Overuse Headache

A Clinical Trial of PRAX-562 in Subjects With Developmental and Epileptic Encephalopathies (DEE)

Study to Compare Efficacy, Safety, and Immunogenicity of LUBT010 (Proposed Ranibizumab Biosimilar) and Lucentis® in Patients With Neovascular AMD

Phase 1/2a Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of WEF-001 as Monotherapy in Advanced KRAS-Mutant Solid Tumours.